"The consolidation with CVS
and Aetna, and Cigna and Express Scripts, is making the whole environment much
more competitive, and that probably impacts the middle-market PBMs more so."
— S&P
analyst Tulip Lim talked with AIS's RADAR
on Drug Benefits about why, with a more competitive market and
looming changes to Part D regulations, industry experts are predicting a
negative outlook for the PBM industry.
No comments:
Post a Comment